Poster
Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients
AACR 2020
Study Background
• Programmed death ligand 1 (PD-L1) is a biomarker associated with response to programmed death-1 (PD-1) and PD-L1 immune checkpoint inhibitors1
• Four immunohistochemistry (IHC) assays for PD-L1 expression have been approved
across a number of tumor types
• Manual assessment of PD-L1 expression is limited by variability in assay and scoring methodology, heterogeneous tumor PD-L1 expression, and interobserver variability
— Interpathologist discordance may increase for tumor samples with low
expression of PD-L1
• Digital quantification may improve the precision of PD-L1 assessment by
overcoming certain limitations observed with manual scoring, as suggested in various tumor types, including non-small cell lung cancer, melanoma (MEL), and urothelial carcinoma (UC)
• Four immunohistochemistry (IHC) assays for PD-L1 expression have been approved
across a number of tumor types
• Manual assessment of PD-L1 expression is limited by variability in assay and scoring methodology, heterogeneous tumor PD-L1 expression, and interobserver variability
— Interpathologist discordance may increase for tumor samples with low
expression of PD-L1
• Digital quantification may improve the precision of PD-L1 assessment by
overcoming certain limitations observed with manual scoring, as suggested in various tumor types, including non-small cell lung cancer, melanoma (MEL), and urothelial carcinoma (UC)
Authors
Duan et al.